Healthcare Services

Oncology Based In-Vivo CRO Market Size Outlook and Demand Growth Across 2026–2030

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Oncology Based In-Vivo CRO Market From 2026 To 2030?

The oncology based in-vivo cro market size has experienced significant expansion in recent years. It is projected to increase from $1.5 billion in 2025 to $1.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. The growth observed in the historical period stems from factors such as increasing demand for preclinical oncology studies, the proliferation of animal model-based research, a rising prevalence of blood cancers and solid tumors, the global expansion of contract research organizations, and more stringent regulatory requirements for preclinical validation.

The oncology based in-vivo cro market size is projected for swift expansion in the upcoming years. This market is anticipated to reach a valuation of $2.54 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.2%. Several factors will fuel this growth during the projected timeframe, including a heightened emphasis on patient-derived xenograft models, greater incorporation of digital data management systems, an expansion in personalized oncology drug development, an uptick in outsourcing in-vivo studies to expert CROs, and wider implementation of automated imaging and monitoring solutions. Key trends anticipated over this period encompass a growing uptake of digital platforms for managing in-vivo studies, augmented application of AI and machine learning in preclinical oncology research, expanded integration of genomic profiling for patient-derived xenograft models, increased automation in both in-vivo testing and data analysis, and enhanced IoT-enabled supervision of lab equipment and study results.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10521&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Oncology Based In-Vivo CRO Market?

The increasing occurrence of cancer is projected to drive the expansion of the oncology-based in-vivo CRO market in the future. Cancer refers to a collection of diseases where abnormal cells divide uncontrollably, extend beyond their normal boundaries, originate in almost any organ or tissue, and spread throughout the body via the blood and lymph systems. The treatment and diagnosis of cancer necessitate innovative drugs and devices, which undergo various preclinical trials, clinical trials, and regulatory processes before market entry. An oncology in-vivo-based CRO is a company contracted by a sponsor company to offer research services, such as performing complete or partial stages of a preclinical in-vivo study (testing with living organisms like animals, plants, or whole cells) before the drug or device is tested in humans. With the rising prevalence of cancer, the demand for novel treatments and therapies has also grown, stimulating the growth of the oncology-based in-vivo CRO market. For instance, the American Cancer Society, a US-based non-profit organization, reported in April 2024 that approximately 609,000 cancer-related deaths and 1.9 million new cancer cases were identified in the country in 2022. An estimated 620,000 cancer deaths are anticipated in 2024, indicating a slight increase in mortality rates. The growing prevalence of cancer is driving the oncology-based in-vitro CRO market.

Which Segments Are Included In The Analysis Of The Oncology Based In-Vivo CRO Market?

The oncology based in-vivo cro market covered in this report is segmented –

1) By Indication: Blood Cancer, Solid Tumors, Other Indications

2) By Model: Syngeneic Model, Xenograft, Patient Derived Xenograft (PDX), Other Models

3) By Application: Pharmaceutical Companies Or Biopharma, Biotechnology Companies, Academic And Research Institutes, CROs Or Contract Research Partners

Subsegments:

1) By Blood Cancer: Leukemia, Lymphoma, Myeloma

2) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

3) By Other Indications: Neuroblastoma, Germ Cell Tumors, Sarcomas

Which Trends Are Shaping The Future Of The Oncology Based In-Vivo CRO Market?

Leading companies in the oncology-based in vivo CRO market are concentrating on developing innovative solutions, such as CAR T-cell therapies, to achieve a competitive edge. CAR T-cell therapy is a type of immunotherapy that utilizes specifically modified T cells to combat cancer. For example, in May 2023, Seattle, a US-based Children’s Hospital and Research Institute, introduced BrainChild Bio to accelerate CAR T-cell therapies for pediatric brain tumors. BrainChild Bio’s initial target for CAR T-cell therapy in pediatric brain tumors will be diffuse intrinsic pontine gliomas (DIPG), an incurable childhood condition that develops in the brainstem. BrainChild Bio operates as a next-generation CAR T-cell treatment platform, incorporating synthetic technologies to maximize the effectiveness of CAR T-cell therapies for CNS malignancies. After securing pediatric registration for DIPG, BrainChild Bio aims to apply its advanced CAR T-cell therapy to treat a wider range of challenging adult and pediatric brain tumors, such as glioblastoma and brain metastases.

Which Key Industry Participants Are Active In The Oncology Based In-Vivo CRO Market?

Major companies operating in the oncology based in-vivo cro market are Crown Bioscience, Charles River Laboratories International Inc., Taconic Biosciences Inc., The Jackson Laboratory, ICON plc., WuXi AppTec Inc., Eurofins Scientific SE, Labcorp Drug Development, Champion Oncology Inc., Xentech SAS, Thermo Fisher Scientific Inc., MI Bioresearch Inc., Covance Inc., Evotec SE, Living Tumor Laboratory, Oncodesign SA, Pharmaron Beijing Co. Ltd., Syngene International Limited, Shanghai Medicilon Inc., Pharmalegacy Laboratories, Oncotest GmbH, Biocytogen LLC

Read the full oncology based in-vivo cro market report here:

https://www.thebusinessresearchcompany.com/report/oncology-based-in-vivo-cro-global-market-report

What Are The Leading Geographic Regions In The Oncology Based In-Vivo CRO Market?

North America was the largest region in the oncology-based in-vivo CRO market in 2025.North America is expected to be the fastest-growing region in the global oncology-based in-vivo CRO market report during the forecast period. The regions covered in the oncology based in-vivo cro market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncology Based In-Vivo CRO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=10521&type=smp

Browse Through More Reports Similar to the Global Oncology Based In-Vivo CRO Market 2026, By The Business Research Company

Specialty Foods Global Market Report

https://www.thebusinessresearchcompany.com/report/specialty-foods-global-market-report

Community Oncology Services Global Market Report

https://www.thebusinessresearchcompany.com/report/community-oncology-services-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795